Tevimbra Injection, Solution, Concentrate
Product Images NDC 72579-125

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Tevimbra (NDC 72579-125). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Beone Medicines Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Tevimbra 01)

A survival probability Kaplan-Meier curve comparing TEVIMBRA (tislelizumab-jsgr) to ICC over time in months. The graph shows overall survival probabilities on the y-axis and time in months on the x-axis, with TEVIMBRA represented by a solid line and ICC by a dashed line. Below the graph, a table lists the number of patients at risk for each group at various time points up to 32 months.*

FDA Label Image

Principal Display Panel (10 mL Vial Carton)

Packaging label for TEVIMBRA (tislelizumab-jsgr) injection, 100 mg/10 mL (10 mg/mL) concentrate for intravenous infusion after dilution. The label indicates a 10 mL single-dose vial, with instructions to dispense with enclosed medication guide and discard unused portion. Manufactured by BeiGene USA, Inc., San Mateo, CA. Storage instruction specifies refrigeration at 2°C to 8°C (36°F to 46°F) and protection from light.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.